Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome
Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome
复制标题
DOI：
10.1038/s41598-019-44472-0
复制
发表时间：
2019-05
影响因子：
4.6
通讯作者：
Misa Tojo;Kaori Shintani-Ishida;Hajime Tsuboi;Mami Nakamura;Nozomi Idota;H. Ikegaya
中科院分区：
文献类型：
--
作者：
Misa Tojo;Kaori Shintani-Ishida;Hajime Tsuboi;Mami Nakamura;Nozomi Idota;H. Ikegaya
五角蛋白3(PTX3)是一种急性时相蛋白，属于五角蛋白超家族。近年来，许多临床研究表明，急性冠脉综合征(ACS)患者血浆PTX3浓度迅速升高。本研究的目的是评估死后血浆PTX3作为致死性急性冠脉综合征标志物的法医学价值。我们比较了疑似致死性急性冠脉综合征患者和对照组的血浆PTX3浓度(例如，窒息和致命损伤导致的即刻死亡)。ACS组包括冠状动脉明显狭窄但无冠状动脉血栓的冠脉狭窄组、冠状动脉内发现血栓的冠脉血栓组和急性心肌梗死后心肌破裂组。冠脉血栓组血浆PTX3浓度显著高于对照组和其他急性冠脉综合征组。死后血浆PTX3浓度高于临床参考值，这可能是由于死后循环中的中性粒细胞释放所致。总之，虽然临床参考值不能应用于死后标本，但死后血浆PTX3浓度可能是致死性急性冠脉综合征发病后立即死亡的有用标记物。
Pentraxin 3 (PTX3) is an acute-phase protein that belongs to the pentraxin superfamily. Recently, many clinical studies have demonstrated that plasma PTX3 concentrations rapidly increase in patients with the acute coronary syndrome (ACS). The aim of this study was to evaluate the forensic utility of postmortem plasma PTX3 as a marker of fatal ACS. We compared the plasma PTX3 concentration in cadavers with suspected fatal ACS to that exhibited in control cases (e.g., asphyxia and immediate death due to a fatal injury). The ACS groups included a coronary stenosis group, which exhibited apparent coronary stenosis, but an absence of coronary thrombi, a coronary thrombi group with thrombi found in the coronary artery, and a group of myocardial rupture following an acute myocardial infarction. The plasma PTX3 concentration was significantly higher in the coronary thrombi group than the control group and other ACS groups. The postmortem plasma PTX3 concentration was higher than the clinical reference values, which appeared to be caused by a postmortem release from circulating neutrophils. In conclusion, although the clinical reference value cannot be applied to postmortem samples, the postmortem plasma PTX3 concentration may be a useful marker of death occurring immediately after the onset of fatal ACS.